The American Journal of Medicine
Volume 122, Issue 3 , Pages 290-300 , March 2009

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

References 

  1. Williams B, Poulter NR, Brown MJ, et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 – BHSIV. J Hum Hypertens. 2004;18:139–185
  2. CG18 Hypertension (persistently high blood pressure) in adults—NICE guideline. Available at: www.nice.org.uk.
  3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 Report). JAMA. 2003;289:2560–2573
  4. The Taskforce for the management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Guidelines for the Management of Arterial Hypertension. J Hypertens. 2007;25:1105–1187
  5. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427–1434
  6. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med. 1994;154:1461–1468
  7. Moser M, Prisant LM. Low-dose combination therapy in hypertension. Am Fam Physician. 1997;56:1275–1279
  8. Rosenthal T, Gavras I. Fixed-dose combinations as first-line treatment for hypertension. Prog Cardiovasc Dis. 2006;48:416–425
  9. Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res. 2005;5:21
  10. Bateman DN, Dean CR, Mucklow JC, et al. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol. 1979;7:357–363
  11. Chalmers JP, Korner PI, Tiller DJ, et al. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. Med J Aust. 1976;1:650–653
  12. Chalmers J, Horvath J, Tiller D, Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Lancet. 1976;2:328–331
  13. Chalmers JP, Wing LMH, Grygiel JJ, et al. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting. Eur J Clin Pharmacol. 1982;22:191–196
  14. Chrysant SG, Chappel C, Farnham J, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol. 1992;32:61–65
  15. Durel LA, Hayashi PJ, Weidler DJ, Schneiderman N. Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. J Clin Pharmacol. 1992;32:564–570
  16. Erwteman TM, Nagelkerke N, Lubsen J, et al. b Blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. BMJ. 1984;289:406–409
  17. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182–188
  18. Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994;8:283–288
  19. Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. Clin Ther. 1993;15:779–787
  20. Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol. 1990;39:327–332
  21. Canter D, Frank GJ, Knapp LE, et al. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens. 1994;8:155–162
  22. Chalmers JP, Morris MJ, Wing LMH, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust NZ J Med. 1986;16:475–480
  23. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med. 1994;154:737–743
  24. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5:17–24
  25. Fernández M, Madero R, González D, et al. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension. 1994;23(Suppl I):I-207–I-210
  26. Kayanakis JG, Baulac L. Comparative study of once-daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension. Br J Clin Pharmacol. 1987;23(Suppl 1):89S–92S
  27. Pool J, Cushman WC, Saini RK, et al. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997;10:117–123
  28. Pordy RC. Cilazapril plus hydrochlorothiazide: improved efficacy without reduced safety in mild to moderate hypertension. Cardiology. 1994;85:311–322
  29. Scholze J, Breitstadt A, Cairns V, et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens. 1993;11:217–221
  30. Burris JF, Weir MR, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA. 1990;263:1507–1512
  31. Pool PE, Applegate WB, Woehler T, et al. A randomized, controlled trial comparing diltiazem, hydrochlorothiazide, and their combination in the therapy of essential hypertension. Pharmacotherapy. 1993;13:487–493
  32. Salvetti A, Magagna A, Innocenti P, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. J Cardiovasc Pharmacol. 1991;17:332–335
  33. Weir MR, Weber MA, Punzi HA, et al. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens. 1992;6:133–138
  34. Wing LMH, Arnolda LF, Harvey PJ, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. J Hypertens. 1997;15:1503–1510
  35. Wald DS, Law M, Mills S, et al. A 16-week, randomized, double-blind placebo-controlled cross-over trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a β-blocker on blood pressure reduction. Clin Ther. 2008;30:2030–2039
  36. Wing LMH, Chalmers JP, West MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens. 1988;10:119–133
  37. Clement DL, De Pue NY, Packet L. Effect of calcium antagonists on ambulatory blood pressure and its variations. J Cardiovasc Pharmacol. 1987;10(Suppl 10):S117–S119
  38. Dargie H, Cleland J, Findlay I, et al. Combination of verapamil and beta-blockers in systemic hypertension. Am J Cardiol. 1986;57:80D–82D
  39. Lyons D, Fowler G, Webster J, et al. An assessment of lacidipine and atenolol in mild to moderate hypertension. Br J Clin Pharmacol. 1994;37:45–51
  40. Maclean D, Mitchell ET, Lewis R, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharmacol. 1990;29:455–463
  41. McInnes GT, Findlay IN, Murray G, et al. Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens. 1985;3(Suppl 3):219–221
  42. Tonkin AL, Wing LMH, Russell AE, et al. Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. J Hypertens. 1990;8:1015–1018
  43. Chan P, Lin C, Tomlinson B, et al. Additive effects of diltiazem and lisinopril in treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens. 1997;10:743–749
  44. Cushman WC, Cohen JD, Jones RP, et al. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens. 1998;11:23–30
  45. Frishman WH, Ram CVS, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol. 1995;35:1060–1066
  46. Kuschnir E, Acuña E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 10 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 1996;18:1213–1224
  47. Levine JH, Ferdinand KC, Cargo P, et al. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens. 1995;8:494–499
  48. Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens. 1998;11:322–327
  49. Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. Br J Clin Pharmacol. 1998;45:491–495
  50. Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. Clin Exp Hypertens. 1999;21:1447–1462
  51. Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. Am J Hypertens. 1997;10:492–499
  52. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol Assess. 2003;7:31
  53. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999;12:797–805
  54. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension (A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy). J Hum Hypertens. 1998;12:861–866
  55. Mackay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278–285
  56. Chrysant SG, Melino M, Karki S, et al. The Combination of Olmesartan Medoxomil and Amlodipine Besylate in Controlling High Blood Pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604
  57. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data from one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  58. Law M, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease. BMJ. 2009;In press
  59. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  60. Lui L, Zhang Y, Liu G, et al. FEVER Study Group The felodipine event reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–2172
  61. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study Research Group (TOMHS) Treatment of Mild Hypertension Study. JAMA. 1998;270:713–724
  62. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes (the second Appropriate Blood Pressure Control in Diabetes (ABCD) trial). Kidney Int. 2002;61:1086–1097
  63. Asselbergs FW, Diercks GFH, Hillege HL, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVENDIT) Investigators Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809–2816

 Funding: None.

 Conflict of Interest: Nicholas J. Wald and Malcolm Law hold patents (EU1272220 and GB2361186) for a combination pill for the prevention of cardiovascular disease (Polypill) and together with David Wald have interests in its development.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)00992-3

doi: 10.1016/j.amjmed.2008.09.038

The American Journal of Medicine
Volume 122, Issue 3 , Pages 290-300 , March 2009

Article Tools

* Image Usage & Resolution